Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Depression in Adolescence, Rumination
Phase NA
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

In the United States, adolescents experience alarmingly high rates of major depression, and gold-standard treatments are only effective for approximately half of patients. Rumination may be a promising treatment target, as it is well-characterized at the neural level and contributes to depression onset, maintenance, and recurrence as well as predicts treatment non-response. Accordingly, the proposed research will investigate whether an innovative mindfulness-based real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention successfully elicits change in the brain circuit underlying rumination to improve clinical outcomes among depressed adolescents.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Mindfulness + fMRI Neurofeedback — Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.

Primary Outcomes

  • Within-person Default Mode Network (DMN) Connectivity (Pre-mbNF procedure)
  • Within-person Default Mode Network (DMN) Connectivity (Post-mbNF procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-10
Completion: 2027-06-30
Eligibility
Age: 13 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Randy P Auerbach, PhD
646-774-5745
rpa2009@cumc.columbia.edu
Simryn Molina, BA
simryn.molina@nyspi.columbia.edu
Susan Whitfield-Gabrieli, PhD
s.whitfield-gabrieli@northeastern.edu
Northeastern University
Interventions
  • Other: Mindfulness + fMRI Neurofeedback — Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
Study Locations (2 sites)
Northeastern University, Boston, Massachusetts 02115 United States
Columbia University Irving Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Ages 13-18 years-old * Written informed assent/consent and parental/guardian permission for 13-17 year-olds or informed consent for 18 year-olds * Tanner puberty stage ≥3 * Meets current diagnostic criteria for MDD * English fluency Exclusion Criteria: * Lifetime history of primary psychotic disorders, bipolar disorder, oppositional defiant disorder, conduct disorder, developmental disorder (e.g., autism), post-traumatic stress disorder, or eating disorders * Substance use disorder, moderate or severe in past 6 months * Active suicidal ideation with a specific plan * History of seizure disorder * Medical or neurological illness (e.g., severe head injury) * MRI contraindications * Current psychotropic medication use other than antidepressant medication * Intelligence quotient (IQ) \<80.
Conditions Cancer, Anxiety, Depressive Symptoms
Phase NA
Enrollment 6516
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the implementation and effectiveness of the psychosocial eHealth intervention, My Wellbeing Guide, on the proposed primary outcome, depressive symptoms, in patients diagnosed with cancer who receive care at Northwestern Medicine and the University of Miami Health System. Eligible patients will be directly contacted by the study team for recruitment. The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up. Participants are randomized into either an intervention application (described above) or a control application (which will provide links to helpful resources for patients with cancer, such as the contact information for cancer support services at Northwestern University and the University of Miami, and the link to the National Cancer Institute website, and the American Cancer Society website.) Control participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: My Wellbeing Guide — The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.

Primary Outcomes

  • Change in depressive symptoms will be evaluated with the Patient-Reported Outcomes Measurement Information System Depression (T1 (prior to starting intervention), T2 (7 weeks post intervention), T3 (6 months post-intervention), T4 (12 months post-intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-12-02
Completion: 2028-07-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 6516 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northwestern University
Collaborators: University of Miami, National Cancer Institute (NCI)
Principal Investigators:
  • Betina Yanez, PhD (PRINCIPAL_INVESTIGATOR) - Northwestern University
Contact Information
Study Contact:
Ro Mercer, BS
312-503-3943
ro.mercer@northwestern.edu
Betina Yanez, PhD
3125035341
betina.yanez@northwestern.edu
Ro Mercer
3125033943
ro.mercer@northwestern.edu
Northwestern University
Interventions
  • Behavioral: My Wellbeing Guide — The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
Study Locations (1 sites)
Northwestern University, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion Criteria: a) having been reached out to by the study team for recruitment; (b) planned treatment and follow-up within the NM or UHealth healthcare system; (c) ≥ 18 years of age; (d) medical chart confirmed diagnosis of a solid or hematological malignancy; (e) elevated depressive symptoms on the PROMIS CAT (score \> or = 55) within the last 3 months; (f) access to the internet; (g) willingness to be randomized; (h) able to read English or Spanish; (i) patients must have signed informed consent prior to registration on study Exclusion Criteria: Note: The investigators will not include any vulnerable populations in this study.
Conditions HIV
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Older gay and bisexual men living with HIV (OGBMLH) are more likely to experience depression and loneliness, which can lead to negative health outcomes. This mixed-methods research study will assess the feasibility and acceptability of the Bridge to Belonging (B2B) intervention. B2B is a peer-delivered, manualized program designed to increase engagement in LGBTQ+-affirming elder services and thereby reduce loneliness and depression among OGBMLH. The program utilizes a) cognitive behavioral therapy-based Friendship Enrichment Program (FEP) to build social skills; b) Peer Mentoring (PM) to model and support engagement in community services; and c) connecting participants to affirming elder services such as meal programs, bereavement groups, social activities, etc. Interventions like B2B are essential to the NIH's goal of improving access to behavioral interventions through advances in HIV/AIDS research.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: B2B Intervention — This 10-session peer-delivered intervention is designed to reduce depression and loneliness among OGBMLH by addressing barriers to engagement in LGBTQ+-affirming community services. The intervention involves group sessions facilitated by trained peer interventionists, drawing on two evidence-based components: the cognitive behavioral therapy-based Friendship Enrichment Program (FEP) to build social skills and Peer Mentoring (PM) to model and support engagement in community services. Sessions are structured around skill-building activities designed to a) reduce stigma-related barriers to community participation, b) create and strengthen social connections, and c) increase confident and motivation to engage in community services. Participants will also receive resource navigation as needed.
  • Behavioral: Control condition — The control condition will involve a resource guide of content related to local LGBTQ+-affirming community service (e.g., information related to community meal programs, social groups, etc.)

Primary Outcomes

  • Feasibility of recruitment (Through end of enrollment, anticipated September 7, 2026)
  • Proportion of Intervention-Arm Participants Completing at Least One B2B Session (Up to 11 weeks)
  • Perceived Feasibility and Satisfaction with B2B, Assessed via Qualitative Exit Interviews (Week 25)
  • Fidelity to B2B Intervention Content, Assessed via Post-Session Fidelity Checklist (Up to 11 weeks)
  • B2B Intervention Satisfaction, Assessed via Modified Client Satisfaction Questionnaire (CSQ-8) (Up to 11 weeks)
  • Retention Feasibility, Proportion of Enrolled Participants Completing Follow-Up Assessment (Through Week 25)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-06
Completion: 2026-12-01
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fenway Community Health
Collaborators: National Institute on Aging (NIA)
Contact Information
Study Contact:
Abigail W Batchelder, PhD, MPH
6173587640
abigail.batchelder@bmc.org
Abigail W Batchelder, PhD, MPH
617-358-7640
abigail.batchelder@bmc.org
Fenway Health
Interventions
  • Behavioral: B2B Intervention — This 10-session peer-delivered intervention is designed to reduce depression and loneliness among OGBMLH by addressing barriers to engagement in LGBTQ+-affirming community services. The intervention involves group sessions facilitated by trained peer interventionists, drawing on two evidence-based components: the cognitive behavioral therapy-based Friendship Enrichment Program (FEP) to build social skills and Peer Mentoring (PM) to model and support engagement in community services. Sessions are structured around skill-building activities designed to a) reduce stigma-related barriers to community participation, b) create and strengthen social connections, and c) increase confident and motivation to engage in community services. Participants will also receive resource navigation as needed.
  • Behavioral: Control condition — The control condition will involve a resource guide of content related to local LGBTQ+-affirming community service (e.g., information related to community meal programs, social groups, etc.)
Study Locations (1 sites)
Fenway Health, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: * HIV+ and provide evidence or documentation of HIV+ status * Willing to release HIV-related health records * Self-identify as a man who has sex with men * Able to provide informed consent in English * Be ≥50 years old * Score at least a 2 on the PHQ-2 OR score at least a 4 on the UCLA Shortened Loneliness Scale Exclusion Criteria: * HIV- * Does not self-identify as a man who has sex with men * Is less than 50 years old * Scores less than 2 on the PHQ-2 AND scores less than 4 on the UCLA Shortened Loneliness Scale

Harlem Strong Mental Health Coalition

NCT05833555
Recruiting
Conditions Stress-related Problem, Depression, Anxi...
Phase NA
Enrollment 700
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Addressing health disparities, especially in the face of coronavirus pandemic, requires an integrated multi-sector equity-focused, community-based approach. This study will examine the impact of Harlem Strong Community Mental Health Collaborative, a community-wide multi-sectoral coalition in which a health insurer works with a network of community-based organizations, medical providers, and behavioral health providers to engage in a network-wide implementation planning process to: (1) problem-solve financing, access, and quality of care barriers, (2) support capacity building for mental health (MH) task-sharing for community health workers, (3) facilitate coordination and collaboration across MH/behavioral health, primary care, and a range of social services, including case management, housing supports, financial education, employment support, and other community resources to improve linkages to services, and (4) identify a set of common MH, social risk, and health metrics and strategies to integrate these metrics into data systems across the network for continuous quality improvement of the system. The long-term goal of our study is to develop sustainable model for task-sharing MH care that will be embedded in a coordinated comprehensive network of services, including primary care, behavioral/MH, social services, and other community resources.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: MH task-sharing training — Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
  • Behavioral: Supervision — Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
  • Behavioral: Learning Collaborative — A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
  • Other: Technology Intervention — To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.

Primary Outcomes

  • Depression - PHQ-9 (6-12 months)
  • Anxiety - GAD-7 (6-12 months)
  • Reach of Screening (0-24 months)
  • Mental Health Service Linkage (0-24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-05
Completion: 2026-08-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City University of New York, School of Public Health
Collaborators: Harlem Congregation for Community Improvement, Inc., Healthfirst
Principal Investigators:
  • Victoria K Ngo, PhD (PRINCIPAL_INVESTIGATOR) - City University of New York
Contact Information
Study Contact:
Srividhya Sharma, PhD, MPH
347-395-7943
Srividhya.Sharma@sph.cuny.edu
Deborah Levine, LCSW
917-549-6155
Deborah.Levine@sph.cuny.edu
Victoria K Ngo, PhD
626-780-7899
victoria.ngo@sph.cuny.edu
CUNY Graduate School of Public Health and Health Policy
Interventions
  • Behavioral: MH task-sharing training — Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
  • Behavioral: Supervision — Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
  • Behavioral: Learning Collaborative — A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
  • Other: Technology Intervention — To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
Study Locations (2 sites)
CUNY Graduate School of Public Health and Health Policy, New York, New York 10025 United States
Harlem Congregation for Community Improvement, New York, New York 10025 United States
Eligibility Criteria
Inclusion Criteria: * Black and Latino adults between 18 and 65 years * Harlem residents from low-income housing developments or receiving primary care services in Harlem * PHQ-4 Total Score ≥3, moderate risk for depression Exclusion Criteria: * Those with risk for depression or anxiety who screen positive for severe mental illness (e.g., psychosis, mania, substance abuse, and high suicide risk) using screening items from the Mini-International Neuropsychiatric Interview will be excluded from the study and referred to MH services at higher levels of care
Conditions Obesity, Weight Loss, Weight Management,...
Phase PHASE4
Enrollment 40
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Obesity is a common chronic disease linked with increased risk for other illnesses and earlier death. Our team and others have shown that many bodily and psychological changes occur when individuals are on calorie-restricted diets. These changes might undermine dietary adherence and help to explain the relatively poor long-term efficacy of diets. These include increased appetite, increased food 'value' and 'wanting' that leads to overconsumption. Other factors include more sensitive sensory cues (e.g., smelling), higher food liking and craving, and a drop in resting energy expenditure (REE). REE has been shown to predict weight regain. The standard care for obesity may include the use of the weight-loss drug CONTRAVE®. The Federal Drug Agency (FDA) and Health Canada have approved this drug for weight management and obesity treatment. Although CONTRAVE® was designed to reduce appetite, food-related impulsivity and cravings, its mechanisms of action are unclear. In other words, the effects of CONTRAVE® on REE, executive function, and brain changes remain unknown in humans. A better understanding of how this drug works on the brain and body could lead to improvements in obesity management in the future. As such, the goal of this research is to study the effects of 4 weeks of CONTRAVE® (+ diet program) vs. control (placebo pill + diet program) on mood, body composition changes, biological/metabolic measures, and brain measures. Adults aged 18-64 with obesity will be randomized to one of two groups: diet + CONTRAVE® (CONTRAVE®, 20 participants) or diet + Placebo (Placebo, 20 participants). Both groups will be assigned the same study procedures for the entire study duration. The only difference is that Group 1 will receive CONTRAVE® while Group 2 will receive a placebo (non-medical) pill. The study design and intervention is as follows: Participants who meet all the telephone screening criteria will be invited to the Clinical EEG \& Neuroimaging Laboratory at The Royal's IMHR for an in-person screening and test-dose session. Participants who are cleared by the study physician, Dr. Pierre Blier, during the in-person screening will be enrolled in the 4-weeks trial. After the in-person screening visit, participants will attend two baseline testing visits (before starting the medication + diet program). The first will occur at the Behavioural and Metabolic Research Unit at the University of Ottawa. During this in-person visit, measures of body composition, resting energy expenditure, appetite, food craving, impulsivity, eating behaviours, taste and odour sensitivity, energy intake, and food preference will be collected. The second baseline visit (within a week of the first one) will occur at The Royal/IMHR. During this visit, participants will be asked to complete questionnaires. They will undergo an EEG recording while resting and performing computer tasks. They will also get a brain imaging scan, during which they are asked to rest and complete…

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Contrave — CONTRAVE® will be titrated up to a therapeutic dose (Naltrexone 32mg/Bupropion 360mg) over a 4-week period as per clinical guidelines, and what is typical in the LEAF clinic. Dose recommendation for CONTRAVE® is tablet based, with each tablet containing 8mg of naltrexone and 90mg of bupropion. The maximum recommended daily dose is two tablets, administered orally, twice daily (32mg/360mg), taken once in the morning and once in the evening. Tablets and dispensing schedule will be done under the oversight of The Royal pharmacy (i.e., they will instruct the participants on the dosing schedule). Medication adherence and side effects will be reported daily using our online data capture system (REDCap) (approximately 1min) starting on the evening of the first dose of administration. If adverse events are significantly concerning, there is a mechanism in place for dealing with such events.
  • Drug: Placebo — Placebo intervention will follow the exact same protocol in terms of tablet numbers as the CONTRAVE intervention. Generic Placebo pills will be packaged by The Royal Pharmacy into blister packs identical to Contrave.
  • Behavioral: Diet Program — All participants will receive an individualized dietary intervention with appropriate energy restriction from registered dietitians at Dr. Shiau's LEAF weight management clinic (called the 4-week BUDS program, which is offered to clients with obesity at the LEAF clinic). The program involves weekly touch points with a registered dietitian, and meal planning/coaching and integrates a partial meal replacement with a commercial shake.

Primary Outcomes

  • MRI Modalities (4 weeks)
  • Changes in body weight/composition (4 weeks)
  • Brain Activity EEG at Rest (4 weeks (pre and post contrave or placebo))
  • Brain Activity During Food Impulsivity Task (4-weeks (pre and post contrave or placebo))
  • Brain Activity During EEFRT Task (4-week (pre and post contrave or placebo))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-07-04
Completion: 2026-07-31
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Royal's Institute of Mental Health Research
Collaborators: University of Ottawa, The Royal Ottawa Mental Health Centre, Bausch Health Americas, Inc., Cheo Research Institute, LEAF Weight Management Clinic
Principal Investigators:
  • Pierre Blier, M.D., Ph.D (PRINCIPAL_INVESTIGATOR) - University of Ottawa
Contact Information
Study Contact:
Natalia Jaworska, Ph.D
613-722-6521
natalia.jaworska@theroyal.ca
Judy Shiau, MD
613-701-1222
info@leafwmc.com
LEAF Weight Managment Clinic
Éric Doucet, PhD
613-562-5800
edoucet@uottawa.ca
Behavioural and Metabolic Research Unit
Interventions
  • Drug: Contrave — CONTRAVE® will be titrated up to a therapeutic dose (Naltrexone 32mg/Bupropion 360mg) over a 4-week period as per clinical guidelines, and what is typical in the LEAF clinic. Dose recommendation for CONTRAVE® is tablet based, with each tablet containing 8mg of naltrexone and 90mg of bupropion. The maximum recommended daily dose is two tablets, administered orally, twice daily (32mg/360mg), taken once in the morning and once in the evening. Tablets and dispensing schedule will be done under the oversight of The Royal pharmacy (i.e., they will instruct the participants on the dosing schedule). Medication adherence and side effects will be reported daily using our online data capture system (REDCap) (approximately 1min) starting on the evening of the first dose of administration. If adverse events are significantly concerning, there is a mechanism in place for dealing with such events.
  • Drug: Placebo — Placebo intervention will follow the exact same protocol in terms of tablet numbers as the CONTRAVE intervention. Generic Placebo pills will be packaged by The Royal Pharmacy into blister packs identical to Contrave.
  • Behavioral: Diet Program — All participants will receive an individualized dietary intervention with appropriate energy restriction from registered dietitians at Dr. Shiau's LEAF weight management clinic (called the 4-week BUDS program, which is offered to clients with obesity at the LEAF clinic). The program involves weekly touch points with a registered dietitian, and meal planning/coaching and integrates a partial meal replacement with a commercial shake.
Study Locations (3 sites)
LEAF Weight Managment Clinic, Ottawa, Ontario K1J 9L3 Canada
Behavioural and Metabolic Research Unit, Ottawa, Ontario K1N 6N5 Canada
University of Ottawa Institute of Mental Health Research, Ottawa, Ontario K1Z 7K4 Canada
Eligibility Criteria
Inclusion Criteria: 1. Participants who are able to provide written informed consent prior to the initiation of any protocol-required procedures 2. Have been referred to the LEAF clinic by their physician or have self-referred to the LEAF clinic for weight loss, and have been deemed appropriate for weight loss treatment offered by the LEAF clinic (i.e., these criteria are at the discretion of the clinical team at the LEAF clinic, outlined below in the exclusion criteria section). 3. Adults: aged 18-64 years of age (gender and sex will be noted; recruitment is all-gender inclusive). 4. Have a BMI\>30. 5. Have normal or corrected vision as some of the study aspects will involve viewing/responding to visual stimuli. 6. Understand and speak English (as instructions for study criteria will be provided in English). 7. Able to participate in the study protocol as described, e.g. have a means of getting to the laboratories and no major mobility issues to the extent that protocols cannot be followed (details below). 8. Access to a secure internet connection (for virtual appointments with members of the LEAF clinic). Exclusion Criteria: 1. Reporting severe depression or reporting significant suicidal ideation, or history of bipolar disorder or psychosis (i.e., major psychiatric condition; this will be ascertained during the screening carried out by research personnel, in keeping with our standard protocols in Dr. Jaworska's laboratory).\*\*\* 2. Current use of antidepressants, thyroid medication, or any medication that could affect appetite, or seizure threshold (e.g.., bupropion, tamoxifen, thioridazine). 3. Uncontrolled hypertension. 4. History of cardiac defects or symptoms suggestive of any cardiac condition (not including coronary artery disease). 5. Presence of diabetes. 6. Current or past history of addictions or substance use disorder, including undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs. 7. History of eating disorder (including Binge Eating Disorder, Bulimia Nervosa or Anorexia Nervosa). 8. History of glaucoma. 9. Personal or family history of seizure disorders. 10. Currently taking MAO inhibitors (within 14 days), pressor agents, coumadin, anticonvulsants, or phenylbutazone, or other bupropion-containing products (such as Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin or Zyban), or CYP2B6 inhibitors (e.g. ticlopidine or clopidogrel). 11. History of thyroid disease, chronic liver, or renal disease. 12. Chronic use of opioid, opiate agonist (Methadone) or partial agonists (Buprenorphine). 13. Currently pregnant or planning to become pregnant during the intervention or currently nursing. Pregnancy urine test will be conducted during the in-person screening session in the laboratory.\*\*\* 14. No known allergy to any of the ingredients in CONTRAVE® (e.g. lactose). 15. Hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption. 16. Current use of obesity medications such as liraglutide or semaglutide or orlistat. 17. Current use of medication indicated in patient living with ADHD (e.g., Vivanse/Concerta) which are known to have metabolic impacts. There are several additional exclusionary criteria, established by research personnel in Dr. Jaworska's laboratory (i.e., not part of LEAF intake) that preclude participation in the brain imaging/magnetic resonance imaging (MRI) and EEG, these include: 18. Severe claustrophobia. 19. Inability to lie still in the scanner for approximately 30min. 20. Metal in the body that cannot be removed and might pose a safety risk to the participant. 21. History of concussion (loss of consciousness for \>5-min). 22. Major neurological illness, such as, epilepsy, stroke, tumours (as this would interfere with the interpretation of the MRI data). 23. Obesity to the extent that the participant cannot fit into the scanner. This will be established by ensuring that the individual can fit into the mock scanner at the Brain Imaging Centre (BIC) of The Royal. If a person cannot fit into the mock scanner, it is unlikely that the person can fit into the real scanner. 24. Testing positive for illicit drugs and cannabis (this will be established using a drug test that will be administered in the Clinical EEG \& Neuroimaging laboratory at the Institute of Mental Health Research \[IMHR\]). Participants who are cannabis users will be invited to participate in the study so long as they can abstain from cannabis use for approximately 2weeks prior to the baseline session and approximately 2weeks before final assessment. Ideally, participants would also abstain from cannabis use during treatment, but, this will not be tested/enforced. 25. Ability to abstain from nicotine/tobacco and caffeine for 3h prior to the baseline testing/EEG recordings, as both substances influence EEG activity. NOTE: If a participant cannot participate in the MRI aspect of the study (i.e., due to the above exclusion criteria), they will still be able to participate in the research study (apart from the MRI component). All MRI/EEG exclusion criteria will be established during the screening/clinical interview carried out by trained research staff from Dr. Jaworska's laboratory (details below). One final exclusion criterion is as follows: 26. Unable to tolerate the test dose of CONTRAVE® (details below). Such individuals would not participate in further elements of the research, but, would continue with their treatment through the LEAF clinic (as determined by the LEAF clinic, per their clinical management program).
Conditions Post Stroke Depression, Post Stroke Fati...
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Background: Light is the most important regulator of circadian rhythm. Naturalistic light, which contains the spectrum of sunlight throughout the day, has been shown to have a positive impact on mental states such as depression and fatigue in stroke and other diseases requiring long-term hospitalization. Depression and fatigue are very common complications after stroke, with a frequency of 30% and 85%, respectively. Both are significantly related to reduced quality of life and early death. Both the causes and pathophysiology behind these complications are unknown, but it is assumed that disturbances (inflammation and cell death) in brain areas and brain networks related to arousal, sleep, circadian rhythm, and the frontal lobe play a role. The hypothesis is that it is possible to detect changes in brain networks related to depression and fatigue by MRI, and that naturalistic light will affect these changes. Method: Stroke patients requiring a minimum of 10 days of rehabilitation are transferred to a neurorehabilitation unit with naturalistic lighting. Examination: Validated tests for fatigue, depression, sleep and cognitive functions. Pathophysiological studies: * MRI focusing on cerebral blood flow, metabolism, and cerebral networks. * Spinal fluid analyses for hormones and markers involved in immunological response as well as wakefulness/arousal and depression. * Sleep assessments.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Naturalistic Light Intervention — Naturalistic light as an Intervention A 24-hour naturalistic lighting scheme is implemented in all areas and rooms in the unit at Rigshospitalet Glostrup with a computer-controlled lighting scheme (ChromaViso, Denmark). The naturalistic lighting scheme is constantly running. The lighting imitate the sunlight rhythm following the principles of Lucas et al.

Primary Outcomes

  • Fatigue and depression (From admission at the rehabilitation unit to the time of discharge aprox. 10 days.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-10
Completion: 2030-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen University Hospital, Rigshospitalet
Collaborators: Chromaviso A/S
Principal Investigators:
  • Anders Sode West, MD, PhD (PRINCIPAL_INVESTIGATOR) - Glostrup University Hospital, Copenhagen
Contact Information
Study Contact:
Anders Sode West, MD, PhD.
+4538634051
anders.sode.west@regionh.dk
Helle Iversen, MD, D.M.Sc
+4538634051
helle.klingenberg.iversen@regionh.dk
Anders S West, MD, PhD
+4521748587
anders.sode.west@regionh.dk
Faculty of Health and Medical Sciences - University of Copenhagen
Interventions
  • Device: Naturalistic Light Intervention — Naturalistic light as an Intervention A 24-hour naturalistic lighting scheme is implemented in all areas and rooms in the unit at Rigshospitalet Glostrup with a computer-controlled lighting scheme (ChromaViso, Denmark). The naturalistic lighting scheme is constantly running. The lighting imitate the sunlight rhythm following the principles of Lucas et al.
Study Locations (1 sites)
Faculty of Health and Medical Sciences - University of Copenhagen, Glostrup Municipality, Capital Region 2600 Denmark
Eligibility Criteria
Inclusion Criteria: * Patients scoring moderate-severe fatigue and/or depression OR NO fatigue and/or depressione which are evaluated as candidates for the rehabilitation unit. Exclusion Criteria: * GCS \< 15 * No functioning nervus opticus or retina in both eyes * Unable to open both eyes * Non communicating patients e.g. severe aphasia (incompetent patients) * Unable to cooperate to the physical examinations * Less than 10 days of hospitalization in the rehabilitation department * Claustrophobia * If the sub investigator finds the study participant unfit to conduct the investigations
Conditions Healthy, Major Depressive Disorder, Trea...
Phase PHASE1
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relative importance of GBP to antidepressant symptom reduction across the induction phase of treatment. If successful, it provides a compelling rationale for a larger prospective investigation of gamma dynamics as a moderator of outcome to varied TRD therapies which impact the balance of cortical excitation and inhibition.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: Ketamine — Ketamine infusion amount is dictated by BMI, sex, and age.
  • Other: Saline — Saline infusion amount is dictated by BMI, sex, and age.

Primary Outcomes

  • Resting State Gamma Power (Before infusion, during infusion, 60-90 minutes after infusion)
  • Auditory Steady State Response Gamma Power (Before infusion, during infusion, 60-90 minutes after infusion)
  • Montgomery-Asberg Depression Rating Scale (MADRS) (Study entry, pre-infusion, study exit visit (up to a month after infusion))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-01-01
Completion: 2026-12-31
Eligibility
Age: 21 Years – 45 Years
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Texas A&M University
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Julia Engelhardt
7136777595
epmadlab@tamu.edu
Nicholas Murphy
713-677-7597
nremurphy@tamu.edu
Jesse Wells
(713) 589-5118
mail@wellsmedicine.com
Wells Medicine
Interventions
  • Drug: Ketamine — Ketamine infusion amount is dictated by BMI, sex, and age.
  • Other: Saline — Saline infusion amount is dictated by BMI, sex, and age.
Study Locations (2 sites)
Wells Medicine, Houston, Texas 77024 United States
Texas A&M (Houston Methodist Hospital Location), Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. General * The criteria for eligibility described here are intended to protect patient welfare where, for example, the administration of ketamine in the context of standardized research (i.e. pharmaco-EEG challenge) would be inadvisable or unsafe. An additional purpose is to decrease psychiatric co-morbidities that may affect the clinical phenomenology or treatment response and thus obscure findings. Further, by virtue of the eligibility criteria the investigators seek to limit variability due to demographic and other factors. 2. All subjects Inclusion Criteria: * Male or Female ages 21-45, inclusive. * Level of understanding sufficient to agree to all tests and examinations required by the protocol. 3. TRD patients * Major depressive disorder (MDD) diagnosis confirmed by MINI, with major depressive episode of at least 4 weeks duration. * MADRS score of 27 or greater. * Meet criteria for treatment resistance, defined as 2+ unsuccessful trials of antidepressants at an adequate dose for at least 6 weeks. * On a stable dose of all psychotropic medications (including antidepressant, antipsychotic, lithium, hypnotic, etc) for a minimum of 4 weeks prior to the Screening period. 4. MDD patients * MDD diagnosis confirmed by the Mini International Neuropsychiatric Interview (MINI), with major depressive episode of at least 4 weeks duration. * MADRS score of less than or equal to 12. * On a stable dose of all psychotropic medications (including antidepressant, antipsychotic, lithium, hypnotic, etc) for a minimum of 4 weeks prior to the Screening period. Exclusion Criteria: * History of MDD with psychotic features, bipolar disorder, schizophrenia spectrum and other psychotic disorders, currently exhibiting psychotic features, or a first-degree relative with a psychotic disorder. * Diagnosed with intellectual disability. * Current major medical problems that affect brain anatomy, neurochemistry, or function, e.g., liver insufficiency, kidney insufficiency, cardiovascular problems, (unstable Arrhythmias, Chronic Heart Failure, Myocardial Infarction (MI) cardiac pacemaker), systemic infections, cancer, active upper respiratory infections, respiratory depression and any brain disorder (seizure disorder, stroke, dementia, degenerative neurologic diseases), and head injury with loss of consciousness for any period of time. * Pregnancy or Breast-feeding. All female participants in reproductive age will undergo pregnancy tests. Female participants will be required to provide evidence of use of contraceptives during the course of the study. * Unable to understand the design and requirements of the study. * Unable to sign the informed consent for any reason. * Patients with a severe personality disorder, including risk for homicide or aggressive behavior, which in the opinion of the investigator has a major impact on the patients' current psychiatric status and would preclude safe study participation. * Patients at serious and imminent risk of suicide and not suitable for an outpatient study, in the judgment of the investigators. * Patients taking medications with known activity at the N-methyl-D-aspartate (NMDA) or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) glutamate receptor \[eg, riluzole, amantadine, lamotrigine, memantine, topiramate, dextromethorphan, D-cycloserine\], or the mu-opioid receptor. * Previous exposure to ketamine or esketamine. * Patients starting hormonal treatment (e.g., estrogen) in the 3 months prior to screening. * Patients with no regular contact with at least one adult. Patients who are un-domiciled are excluded. * Body mass index (BMI) \>=40 kg/m2. * Active eating disorder or cognitive deficit affecting the regulation of food intake. * Current or recent course of electroconvulsive therapy (ECT) (past month). * History of deep brain stimulation (DBS), vagal nerve stimulation (VNS) implantation, or other form of psychosurgery * Recently started cognitive behavioral therapy (CBT) (past month). * Patients taking \>6mg/day lorazepam (benzodiazepine)-equivalents. Patients with lower and/or infrequent use of benzodiazepines will be required to discontinue their dose on the morning (noting that this is already per protocol at the partner ketamine clinic). * Patients taking prescription opioids. Over the counter pain medications are proscribed on infusion days. * Dietary supplements affecting central nervous system (CNS) function will be discontinued before the study start. This will include supplementation of glutamate, serotonin (e.g. 5-hydroxytryptophan(HTP), St. John's Wort), creatine, γ-Aminobutyric acid (GABA). * Patients habitually consuming legal cannabis products containing cannabidiol (CBD) or delta-8-tetrahydrocannabinol (THC). * The participant has a known ketamine allergy or is taking any medication that may interact with ketamine.
Conditions Substance Abuse, Suicide, Depression
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Suicide is the 10th leading cause of death for Americans of all ages and more people in the United States now die from suicide than die from car accidents. Although death by firearm remains the most common cause of suicide in the United States, an intentional overdose of substance usage such as prescription opioids accounts for over 5,000 suicides per year. In 2017, more than 70,000 drug overdose deaths occurred, making it the leading cause of injury-related death, and well over half (67.8%) involved opioids. The dramatic increase in opioid overdose raises concerns about their contribution to suicidal outcomes (e.g., suicidal behavior, ideation, and attempts). Abuse of prescription opioids is characterized by the persistence of opioid use despite negative consequences. The neurobiology of opioid abuse involves the mesolimbic dopamine systems as the main neural substrate for opioid reward, and altered dopamine release in this system plays a role in opioid abuse. Moreover, the cortico-striatal system, especially the orbitofrontal cortex (OFC), has been associated with the abuse of many substances, including opioids and alcohol. Structural brain alterations in frontal areas, particularly the OFC, may cause executive control dysfunctions of mood which are highly associated with suicidal ideation. Recent preclinical work has shown that higher input from the OFC to the dorsal striatum (dSTR) is associated with compulsive reward-seeking behavior despite negative effects (e.g., punishment). In this study, the investigators propose that OFC/dSTR connectivity may be one neural differentiator that distinguishes between those who become compulsive users after initial opioid use and those that do not. Moreover, suicidal patients among those who become compulsive users may have higher OFC/dSTR connectivity compared to non-suicidal patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Repetitive Transcranial Magnetic Stimulation (rTMS) — 5 Sessions of rTMS - brief single pulse TMS or short TMS pulse bursts consisting of 2-5 pulses delivered per second at a standard intensity. If a brief single pulse TMS is applied, a standard single pulse TMS procedure will be used - This procedure consists of 10 trains of 180 seconds duration and each train will be separated by at least 30 seconds. If short TMS pulse bursts are applied, a standard theta-burst TMS procedure will be used - This procedure consists of TMS triplets (i.e., 3 pulses) that repeat for 10 trains of a total duration of 40-190 seconds and these bursts will be separated by at least 6 seconds and each train will be separated by at least 30 seconds
  • Device: sham rTMS — 5 sessions of sham rTMS

Primary Outcomes

  • Functional Connectivity between the orbitofrontal cortex (OFC) and dorsal striatum in opioid users or opioid-related patients versus healthy subjects (1 day)
  • rTMS changes in dorsal striatum responses between those receiving active stimulation versus sham stimulation (7 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-01-04
Completion: 2027-03-31
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baylor College of Medicine
Collaborators: American Foundation for Suicide Prevention, National Institute on Drug Abuse (NIDA)
Contact Information
Study Contact:
Hyuntaek Oh, PhD
713-275-5019
hoh@menninger.edu
Taylor Ly
713-275-5594
TLy1@menninger.edu
Hyuntaek Oh, PhD
713-275-5019
hoh@menninger.edu
The Menninger Clinic
Interventions
  • Device: Repetitive Transcranial Magnetic Stimulation (rTMS) — 5 Sessions of rTMS - brief single pulse TMS or short TMS pulse bursts consisting of 2-5 pulses delivered per second at a standard intensity. If a brief single pulse TMS is applied, a standard single pulse TMS procedure will be used - This procedure consists of 10 trains of 180 seconds duration and each train will be separated by at least 30 seconds. If short TMS pulse bursts are applied, a standard theta-burst TMS procedure will be used - This procedure consists of TMS triplets (i.e., 3 pulses) that repeat for 10 trains of a total duration of 40-190 seconds and these bursts will be separated by at least 6 seconds and each train will be separated by at least 30 seconds
  • Device: sham rTMS — 5 sessions of sham rTMS
Study Locations (1 sites)
The Menninger Clinic, Houston, Texas 77035 United States
Eligibility Criteria
Inclusion Criteria Opioid Use Patients: Each potential subject will be eligible for inclusion in this study only if the specific criteria listed below are met: * Be male or female aged 18-60 years old * Participation in H-22611; * Meets a World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (WHO-ASSIST) score of 4+ in the opioid category; * Has depressive symptoms according to the Patient Health Questionnaire (PHQ)-9; * Has active suicidal thoughts according to Suicide Behaviors Questionnaire-Revised (SBQ-R); * Be able to verbalize understanding of consent form, able to provide written informed consent, and verbalize willingness to complete study procedures; * Female subjects must be non-nursing and not pregnant at the times of fMRI experiments and rTMS treatment; * Has no contraindications to MRI (pacemaker, cochlear implants, metal in eyes, other metal implants, etc.); Meets the pre-screening magnetic resonance imaging (MRI) questions provided by the Center for Advanced MR Imaging (CAMRI); * Has no contraindications to TMS (any types of non-removable metal in their head except the mouth, or within 12 inches of the coil, etc.). Inclusion Criteria Healthy Controls: Each potential subject will be eligible for inclusion in this study only if the specific criteria listed below are met: * Be male or female aged 18-60 years old; * No history of severe medical or neurological illnesses per history; * Be able to verbalize understanding of consent form, able to provide written informed consent, and verbalize willingness to complete study procedures; * Female subjects must be non-nursing and not pregnant at the time of fMRI experiments; * Has no contraindications to MRI (pacemaker, cochlear implants, metal in eyes, other metal implants, etc.): Meets the pre-screening MRI questions provided by the Center for Advanced MR Imaging (CAMRI); * Has no contraindications to TMS (any types of non-removable metal in their head except the mouth, or within 12 inches of the TMS coil, etc.). Exclusion Criteria: Any potential subject who meets any of the following criteria will be excluded from participating in the study if s/he has * In the opinion of the clinician and the research team at admission, be expected to fail to complete the study protocol due to not tolerable to receive rTMS; * Unable to understand the design and requirements of the study; * Unable to sign informed consent for any reason; * Has an unstable medical condition, including Acquired immunodeficiency syndrome (AIDS), acute hepatitis, active TB, unstable cardiac disease, unstable diabetes, hepatic or renal insufficiency; * Female subjects who are pregnant or nursing; * Contraindications to MRI (pacemaker, cochlear implants, metal in the eye, other metal implants, etc.): Do not meet the pre-screening MRI questions provided by the CAMRI; * Contraindications to the noninvasive brain stimulation (NIBS) (any types of non- removable metal in their head except the mouth, or within 12 inches of the coil, etc.) Additional exclusion criteria for the TMS experiments are based on the recommendations described by the international consensus panel on brain stimulation; * Non-English speaking subjects (we do not have the staff and resources to include other languages)
Conditions Depression, Postpartum
Phase NA
Enrollment 1000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

In recent years, fatherhood has changed considerably. Fathers are now more involved during the perinatal period, with their partner but also in caring for the child. Investigators now know that this period is also a source of major psychological upheaval, identity crisis, apprehension and anxiety for men. These upheavals can lead to depression that must be detected and treated as early as possible. This is an easy screening to perform using the EPDS (Edinburgh Postnatal Depression Scale). Currently, the EPDS is the most widely used self-questionnaire to assess the risk of depression in women during the perinatal period. Indeed, it is systematically recommended in many countries. It is starting to be used for the same purpose in the perinatal period in men, although the scale has not been validated in a representative sample of men in the pre- or post-natal period. The main objective is to validate the use of the EPDS scale as a screening tool for postnatal depression in a population of French fathers. They complete the PH-Q9, EPDS and socio-demographic questionnaires online at inclusion and 6 to 8 weeks after the birth of their child. Fathers included at the maternity ward also too Mini International Neuropsychiatric Interview (MINI) at inclusion.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Mini International Neuropsychiatric Interview — Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression
  • Other: EPDS book — PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.

Primary Outcomes

  • Mini International Neuropsychiatric Interview (at inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-11
Completion: 2027-03-12
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Groupe Hospitalier du Havre
Contact Information
Study Contact:
Angélique PICARD, project coordinator
+33232734856
angelique.picard@ch-havre.fr
Christophe FRUIT, CRA
+33232734857
cellule.rechercheclinique@ch-havre.fr
PICARD Angélique
0232734856
Le Havre hospital - site Jacques Monod
Interventions
  • Diagnostic Test: Mini International Neuropsychiatric Interview — Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression
  • Other: EPDS book — PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.
Study Locations (2 sites)
Antoine-Béclère hospital AP-HP, Clamart, 92140 France
Le Havre hospital - site Jacques Monod, Montivilliers, 76290 France
Eligibility Criteria
Inclusion Criteria: * All fathers whose baby is 10 days old or less Exclusion Criteria: * People with a poor understanding of spoken or written French * Minors * Persons under court protection, guardianship or curatorship
Conditions Major Depressive Disorder (MDD), General...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The World Health Organization Composite International Diagnostic Interview (CIDI) is a fully structured diagnostic tool designed for lay interviewers to assess the prevalence of mental and substance use disorders. Earlier versions, such as the CIDI 3.0, demonstrated acceptable individual-level concordance with clinical assessments based on DSM-IV criteria (Haro et al. 2006). The latest iteration (CIDI 5.0) has been updated to operationalize DSM-5 criteria. Recent evidence from a large-scale, community-based national study in Qatar suggests that under DSM-5 criteria (Khaled et al. 2024), after recalibration, the CIDI 5.0 maintains high specificity (91.9% for MDD, 94.7% for GAD, and 85.5% for PTSD). Sensitivity suggested CIDI diagnoses aligned closely with clinical "gold standard" diagnoses (51.5% for MDD, 50.7% for GAD, and 77.3% for PTSD). Despite the evidence from Qatar, there remains a lack of evidence regarding the validity of the CIDI 5.0 in population-based studies. Therefore, this study aims to evaluate the diagnostic validity of the CIDI 5.0 for Lifetime MDD, GAD, and PTSD, using the Structured Clinical Interview for DSM-5 (SCID-5) as the definitive clinical gold standard.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: CIDI-5 — The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). Trained interviewers will administer selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes. To validate the diagnoses in the CIDI-5 group, investigators will conduct clinical re-interviews of 3 selected CIDI-5 diagnoses: major depressive disorder (MDD), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) using the Structured Clinician Interview for DSM-5 (SCID) by a trained mental health professional with previous experience using SCID.

Primary Outcomes

  • Depression (Immediately following intervention or recruitment)
  • Worry and Anxiety (Immediately following intervention or recruitment)
  • Stressful Experiences (Immediately following intervention or recruitment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-14
Completion: 2028-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Contact Information
Study Contact:
Yoona Kim, PhD
+852 3917 9109
yoonak@hku.hk
Yoona Kim, PhD
+852 3917 9109
yoonak@hku.hk
The University of Hong Kong
Interventions
  • Diagnostic Test: CIDI-5 — The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). Trained interviewers will administer selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes. To validate the diagnoses in the CIDI-5 group, investigators will conduct clinical re-interviews of 3 selected CIDI-5 diagnoses: major depressive disorder (MDD), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) using the Structured Clinician Interview for DSM-5 (SCID) by a trained mental health professional with previous experience using SCID.
Study Locations (1 sites)
The University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * All household members aged 18 years old and over are randomly sampled from the Census and Statistics Department List of Quarters * Live in the address sampled from the Census and Statistics Department List of Quarters * Reside in Hong Kong for at least six months in the past year * Able to read and communicate in Chinese or English * Without linguistic or cognitive difficulties Exclusion Criteria: * Domestic workers
Conditions Hypertension, Blood Pressure, Drug Use
Phase PHASE4
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently. The investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Alisartan, Amlodipine besylate — Drugs will be taken once daily at 6:00-10:00.
  • Drug: Alisartan, Amlodipine besylate — Drugs will be taken once daily at 20:00-24:00.

Primary Outcomes

  • Nighttime systolic BP reduction in mmHg (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-01-28
Completion: 2026-09-30
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yan Li
Contact Information
Study Contact:
Li Yan, Professor
021-64370045
liyanshcn@163.com
Yan Li, Professor
021-64370045
liyanshcn@163.com
Ruijin Hospital
Yan Li, Professor
Ruijin Hospital
Interventions
  • Drug: Alisartan, Amlodipine besylate — Drugs will be taken once daily at 6:00-10:00.
  • Drug: Alisartan, Amlodipine besylate — Drugs will be taken once daily at 20:00-24:00.
Study Locations (1 sites)
Ruijin Hospital, Shanghai, Shanghai Municipality 200025 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female patients aged 18-70 years old; 2. Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks; 3. In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP \< 100 mmHg; 4. The average 24-hour systolic BP ≥130mmHg, daytime systolic BP ≥ 135 mmHg, and nighttime systolic BP ≥ 120 mmHg; 5. The average of bilateral brachial-ankle pulse wave velocity ≥14m/s; 6. Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself. Exclusion Criteria: 1. Secondary hypertension; 2. Concomitant obstructive sleep apnea (STOP-BANG score ≥ 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP; 3. Need to work at night; 4. Ambulatory BP monitoring was invalid (\<70% valid readings, or \<20 daytime readings or \<7 nighttime readings); 5. Concomitant diseases that need taking medications influencing BP; 6. Coronary heart disease, myocardial infarction or stroke within recent 6 months; 7. Atrial fibrillation or frequent arrhythmia; 8. Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine ≥176 µmol/L; and plasma potassium ≥5.5 mmol/L or ≤3.5mmol/L; 9. Pregnant or lactating women; 10. Contraindications of angiotensin II receptor blocker or calcium channel blocker; 11. Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.
Conditions Glaucoma, Primary Open Angle Glaucoma (P...
Phase NA
Enrollment 108
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial. This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence. The trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function. The results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: BrudyGlauco — Participants in the experimental group will receive BrudyGlauco, a dietary supplement containing docosahexaenoic acid (DHA) and citicoline.
  • Dietary Supplement: Placebo — Participants in the placebo comparator group will receive identical-looking capsules containing sunflower oil.

Primary Outcomes

  • Change from baseline in visual function assessed by Mean Deviation (MD) at 12 months (12 months)
  • Change from baseline in visual function assessed by Visual Field Index (VFI) at 12 months (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2027-05-30
Eligibility
Age: 50 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Catala de Retina
Collaborators: Hospital de la Esperanza
Contact Information
Study Contact:
Alfonso Antón Lopez Antón Lopez, Prof MD PhD
+34 93 4340553
alfonso.anton@icrcat.com
Estela del Mar Sánchez Sotano, Biomedical science
93 253 16 47
estela.sanchez@icrcat.com
Estela del Mar Sánchez Sotano
662397315
estelasanchezs37@gmail.com
Institut Català de Retina
Interventions
  • Dietary Supplement: BrudyGlauco — Participants in the experimental group will receive BrudyGlauco, a dietary supplement containing docosahexaenoic acid (DHA) and citicoline.
  • Dietary Supplement: Placebo — Participants in the placebo comparator group will receive identical-looking capsules containing sunflower oil.
Study Locations (2 sites)
Institut Català de Retina, Barcelona, Barcelona 08022 Spain
Hospital del Mar | Centre Esperança, Barcelona, Barcelona 08024 Spain
Eligibility Criteria
Inclusion Criteria: 1. Patients with chronic glaucoma (primary or secondary, open-angle or closed-angle) diagnosed in at least one eye, meeting the following criteria: Structural damage: Thinning of the neuroretinal rim, peripapillary hemorrhage, or reduction in the nerve fiber layer, confirmed by OCT or color fundus photography. Functional damage: At least 3 contiguous abnormal points outside the 95% confidence limit in the pattern deviation map of the visual field. 2. At least 4 reliable visual field (VF) tests before study enrollment. 3. Age between 50 and 75 years. 4. If both eyes meet the inclusion criteria, the eye with the worst Mean Deviation (MD) will be selected as the study eye. Exclusion Criteria: 1. Use of any vitamin or nutraceutical supplement in the month prior to screening. 2. Any condition that could alter visual field testing, including: Neurological diseases. Retinal diseases. Advanced cataracts. Treatment with Lyrica (Pregabalin) due to its effect on visual fields. 3. Hypersensitivity to acetylsalicylic acid (aspirin) (cross-reactivity risk with citicoline). 4. Ocular surgery or laser treatment in the 3 months prior to enrollment or planned during the study. 5. Mean Deviation (MD) of the visual field worse than -20 dB or better than -3 dB.